explore -WSS

explore

author：comprehensive 2025-09-06 01:52:19 - browse：5

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Clinicians often fail to acknowledge the pain caused by long Covid

WSS

Will Ozempic

The explosion of genetic testing requires a new approach

CEOs share strategies for surviving biotech slump

HHS leader on health, climate change and biopharma emissions

STAT Readout Newsletter: Today's biggest biotech updates

U.S. death rates show how politics are affecting public health

focus

explore

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Should insurance cover cosmetic surgery?

Duchenne breakthrough therapy leaves behind pioneering families

Unmasking the 'centricity' illusion in clinical trials

Medical leaders decry Supreme Court decision on affirmative action

UnitedHealth’s board chair also owns a personal investment firm

Drug repurposing or repositioning? The language matters

Medical students need to learn the potent medicine of empathy

ChatGPT in medicine: STAT answers readers' burning questions

The EU Joint Clinical Assessment needs to live up to its promise

explore

Achieving telehealth equity for people with hearing loss

FDA struggles to regulate food additives, sometimes for decades

Pharmacists can make shortage drugs, but at what cost?

Should insurance cover cosmetic surgery?

STAT Readout Newsletter: Today's biggest biotech updates

J&J reports mixed data on next

entertainment

Wikipedia

entertainment

leisure time